Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DE-111 vs Tafluprost vs Tafluprost/Timolol in Glaucoma/Ocular Hypertension
NCT01342081Phase 3Completed
- Sponsor
- Santen Pharmaceutical
- Start
- May 2011
- Primary completion
- Sep 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tafluprost + timolol in primary open-angle glaucoma (POAG) and ocular hypertension (3 arms), sponsored by Santen Pharmaceutical. Primary endpoint: Change From Baseline in Mean Diurnal IOP at End of Study at Week 4. Started May 2011; status: completed.
02
Drugs
tafluprost + timolol
03
Conditions
primary open-angle glaucoma (POAG)ocular hypertension
Beyond the preview
Go deeper on NCT01342081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01342081.